等待开盘 04-01 09:30:00 美东时间
+5.030
+7.35%
今日重点评级关注:Guggenheim:维持Cabaletta Bio"买入"评级,目标价从15美元升至16美元;HC Wainwright & Co.:维持Palvella Therapeutics"买入"评级,目标价从255美元升至270美元
03-25 10:31
In the ever-evolving and intensely competitive business landscape, conducting a...
03-23 17:59
今日重点评级关注:瑞穗:维持RELMADA THERAPEUTICS"跑赢大市"评级,目标价从10美元升至19美元;奥本海默:维持Pelthos Therapeutics"跑赢大市"评级,目标价从60美元升至62美元
03-23 13:53
Viking Holdings Ltd. director Tore Myrholt files initial beneficial ownership statement Viking filed an initial statement of beneficial ownership naming Tore Myrholt as a director. The filing reported 5,500 ordinary shares beneficially owned indirectly. The shares were held through Enodden AS. Discl
03-18 21:54
Viking Holdings Ltd. Chairman and CEO Torstein Hagen files initial beneficial ownership statement Torstein Hagen, chairman and CEO of Viking Holdings, filed an initial statement of beneficial ownership. He reported direct beneficial ownership of 357,702 ordinary shares. He also reported indirect ben
03-18 21:47
Viking Holdings Ltd. EVP Jeffrey Dash files Form 3 initial beneficial ownership statement Viking Holdings reported an initial statement of beneficial ownership for Jeffrey Dash, an officer serving as EVP, Business Development. Dash reported direct beneficial ownership of 208,680 ordinary shares. The
03-18 21:43
Viking Holdings Ltd. EVP Group Operations Anton Hofmann files initial beneficial ownership statement Viking reported an initial statement of beneficial ownership by Anton Hofmann, an officer serving as EVP, Group Operations. Hofmann reported direct beneficial ownership of 0.58 million ordinary share
03-18 21:40
Viking Holdings Ltd. director Richard David Fear files initial beneficial ownership statement Viking Holdings filed an initial statement of beneficial ownership naming Richard David Fear as a director. The filing lists no securities as beneficially owned by Fear. The date of the event requiring the
03-18 21:36
Viking Holdings Ltd (($VIK)) has held its Q4 earnings call. Read on for the mai...
03-17 08:10
今日重点评级关注:LUCID CAPITAL MARKETS:上调INmune Bio评级至"买入" 目标价从2美元升至9美元;Clear Street:维持MoonLake Immunotherapeutics Class A"买入"评级,目标价从45美元升至70美元
03-12 12:34